Margriet R Timmer1, Shannon M Brankley2, Emmanuel C Gorospe3, Gang Sun3, Lori S Lutzke3, Prasad G Iyer3, Kevin C Halling2, Kausilia K Krishnadath4, Kenneth K Wang3. 1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA; Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands. 2. Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA. 3. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. 4. Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Endoscopic therapy for the treatment of high-grade dysplasia (HGD) and intramucosal cancer (IMC) in Barrett's esophagus (BE) may not always result in complete remission of dysplasia (CRD). OBJECTIVE: To determine whether genetic alterations in the Barrett's mucosa can predict response to endoscopic therapy. DESIGN: Retrospective cohort study. SETTING: Tertiary-care institution. PATIENTS: Selected patients who underwent endoscopic therapy for BE containing HGD/IMC between 2003 and 2010. INTERVENTIONS: Endoscopic therapy combining mucosal resection and different ablation modalities was performed based on patient characteristics, endoscopic findings, and technique evolution. Fluorescence in situ hybridization was used to evaluate genetic alterations on baseline endoscopic cytology brushings by using probes directed to loci 8q24 (MYC), 9p21 (CDKN2A; alias P16), 17q12 (ERBB2; alias Her-2/neu), and 20q13.2 (ZNF217). MAIN OUTCOME MEASUREMENTS: Genetic biomarkers predicting achievement of CRD after endoscopic therapy. RESULTS: A total of 181 patients were included (145 men; 66 ± 10 years of age). There were 130 patients (72%) who responded to endoscopic therapy with CRD. Multiple gains detected by fluorescence in situ hybridization was found to be a negative predictor (hazard ratio 0.57; 95% confidence interval, 0.40-0.82) after adjusting for potential clinical confounders. Similar results were found when analyses were restricted to patients (n = 66) undergoing radiofrequency ablation (hazard ratio 0.58; 95% confidence interval, 0.31-1.09). LIMITATIONS: Retrospective study, heterogeneity of treatment modalities. CONCLUSION: Patients with multiple gains detected by brush cytology specimens may have a lower response rate to endoscopic therapy. The presence of multiple gains can be an adjunct to standard histology in prognosticating BE patients with HGD/IMC undergoing endoscopic therapy.
BACKGROUND: Endoscopic therapy for the treatment of high-grade dysplasia (HGD) and intramucosal cancer (IMC) in Barrett's esophagus (BE) may not always result in complete remission of dysplasia (CRD). OBJECTIVE: To determine whether genetic alterations in the Barrett's mucosa can predict response to endoscopic therapy. DESIGN: Retrospective cohort study. SETTING: Tertiary-care institution. PATIENTS: Selected patients who underwent endoscopic therapy for BE containing HGD/IMC between 2003 and 2010. INTERVENTIONS: Endoscopic therapy combining mucosal resection and different ablation modalities was performed based on patient characteristics, endoscopic findings, and technique evolution. Fluorescence in situ hybridization was used to evaluate genetic alterations on baseline endoscopic cytology brushings by using probes directed to loci 8q24 (MYC), 9p21 (CDKN2A; alias P16), 17q12 (ERBB2; alias Her-2/neu), and 20q13.2 (ZNF217). MAIN OUTCOME MEASUREMENTS: Genetic biomarkers predicting achievement of CRD after endoscopic therapy. RESULTS: A total of 181 patients were included (145 men; 66 ± 10 years of age). There were 130 patients (72%) who responded to endoscopic therapy with CRD. Multiple gains detected by fluorescence in situ hybridization was found to be a negative predictor (hazard ratio 0.57; 95% confidence interval, 0.40-0.82) after adjusting for potential clinical confounders. Similar results were found when analyses were restricted to patients (n = 66) undergoing radiofrequency ablation (hazard ratio 0.58; 95% confidence interval, 0.31-1.09). LIMITATIONS: Retrospective study, heterogeneity of treatment modalities. CONCLUSION:Patients with multiple gains detected by brush cytology specimens may have a lower response rate to endoscopic therapy. The presence of multiple gains can be an adjunct to standard histology in prognosticating BE patients with HGD/IMC undergoing endoscopic therapy.
Authors: Elizabeth L Bird-Lieberman; Jason M Dunn; Helen G Coleman; Pierre Lao-Sirieix; Dahmane Oukrif; Christina E Moore; Sibu Varghese; Brian T Johnston; Kenneth Arthur; Damian T McManus; Marco R Novelli; Maria O'Donovan; Christopher R Cardwell; Laurence B Lovat; Liam J Murray; Rebecca C Fitzgerald Journal: Gastroenterology Date: 2012-07-03 Impact factor: 22.682
Authors: Mario Anders; Christina Bähr; Muhammad Abbas El-Masry; Andreas H Marx; Martin Koch; Stefan Seewald; Guido Schachschal; Andreas Adler; Nib Soehendra; Jakob Izbicki; Peter Neuhaus; Heiko Pohl; Thomas Rösch Journal: Gut Date: 2014-01-03 Impact factor: 23.059
Authors: Rehan J Haidry; Jason M Dunn; Mohammed A Butt; Matthew G Burnell; Abhinav Gupta; Sarah Green; Haroon Miah; Howard L Smart; Pradeep Bhandari; Lesley Ann Smith; Robert Willert; Grant Fullarton; John Morris; Massimo Di Pietro; Charles Gordon; Ian Penman; Hugh Barr; Praful Patel; Philip Boger; Neel Kapoor; Brinder Mahon; Jonathon Hoare; Ravi Narayanasamy; Dermot O'Toole; Edward Cheong; Natalie C Direkze; Yeng Ang; Marco Novelli; Matthew R Banks; Laurence Bruce Lovat Journal: Gastroenterology Date: 2013-03-28 Impact factor: 22.682
Authors: B J Reid; L J Prevo; P C Galipeau; C A Sanchez; G Longton; D S Levine; P L Blount; P S Rabinovitch Journal: Am J Gastroenterol Date: 2001-10 Impact factor: 10.864
Authors: Shannon M Brankley; Emily G Barr Fritcher; Thomas C Smyrk; Matthew E Keeney; Michael B Campion; Jesse S Voss; Amy C Clayton; Kenneth K Wang; Lori S Lutzke; Benjamin R Kipp; Kevin C Halling Journal: Hum Pathol Date: 2011-08-04 Impact factor: 3.466
Authors: Carlos Guarner-Argente; Thomas Buoncristiano; Emma E Furth; Gary W Falk; Gregory G Ginsberg Journal: Gastrointest Endosc Date: 2013-02 Impact factor: 9.427
Authors: William J Bulsiewicz; Hannah P Kim; Evan S Dellon; Cary C Cotton; Sarina Pasricha; Ryan D Madanick; Melissa B Spacek; Susan E Bream; Xiaoxin Chen; Roy C Orlando; Nicholas J Shaheen Journal: Clin Gastroenterol Hepatol Date: 2012-10-25 Impact factor: 11.382
Authors: Sebastian S Zeki; Rehan Haidry; Trevor A Graham; Manuel Rodriguez-Justo; Marco Novelli; Jonathon Hoare; Jason Dunn; Nicholas A Wright; Laurence B Lovat; Stuart A C McDonald Journal: Am J Gastroenterol Date: 2013-08-13 Impact factor: 10.864
Authors: Angelique Levert-Mignon; Michael J Bourke; Sarah J Lord; Andrew C Taylor; Antony R Wettstein; Melanie Edwards; Natalia K Botelho; Rebecca Sonson; Chatura Jayasekera; Oliver M Fisher; Melissa L Thomas; Finlay Macrae; Damian J Hussey; David I Watson; Reginald V Lord Journal: United European Gastroenterol J Date: 2016-07-07 Impact factor: 4.623
Authors: Manisha Bajpai; Anshuman Panda; Kristen Birudaraju; James Van Gurp; Amitabh Chak; Kiron M Das; Parisa Javidian; Hana Aviv Journal: Front Genet Date: 2021-06-09 Impact factor: 4.599
Authors: Christopher J Bowman; Ruth Zhang; Dana Balitzer; Dongliang Wang; Peter S Rabinovitch; Bence P Kővári; Aras N Mattis; Sanjay Kakar; Gregory Y Lauwers; Won-Tak Choi Journal: Mod Pathol Date: 2021-06-09 Impact factor: 7.842